Early-Stage Esophageal Adenocarcinoma

Although T2,N0,M0 esophageal adenocarcinoma is grouped with other locoregional disease by NCCN, no consensus exists about how it should be treated. One of the inherent complexities of treating T2,N0,M0 esophageal adenocarcinoma is the inaccuracy of the clinical staging. In addition, conflicting evidence exists about whether the addition of neoadjuvant therapy to esophagectomy adds a benefit. A 52-year-old patient recently seen at the Robert H. Lurie Comprehensive Cancer Center illustrates the complexity of these issues.

Target Audience

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the rationale for the management of patients with early stage esophageal adenocarcinoma
  • Identify appropriate mechanisms for the staging of early stage esophageal adenocarcinoma
Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
06/10/2013
Course expires: 
06/10/2014
Cost:
$0.00

Ariel Polish, MD
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine, Northwestern University
Chicago, Illinois

Mary F. Mulcahy, MD
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine, Northwestern University
Chicago, Illinois

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing